[Connection between the early phases of kidney disease and the metabolic syndrome].

[1]  Carlos Iribarren,et al.  Body Mass Index and Risk for End-Stage Renal Disease , 2006, Annals of Internal Medicine.

[2]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[3]  J. Paramo,et al.  Prothrombin Fragment 1+2 Is Associated With Carotid Intima-Media Thickness in Subjects Free of Clinical Cardiovascular Disease , 2004, Stroke.

[4]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.

[5]  M. Fujishima,et al.  Effect of hyperinsulinemia on renal function in a general Japanese population: the Hisayama study. , 1999, Kidney international.

[6]  Tom Greene,et al.  Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.

[7]  L. Bouter,et al.  Metabolic Syndrome and 10-Year Cardiovascular Disease Risk in the Hoorn Study , 2005, Circulation.

[8]  E. Ritz.  Heart and kidney: fatal twins? , 2006, The American journal of medicine.

[9]  Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. , 2005, Kidney international. Supplement.

[10]  K. Iseki,et al.  Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. , 2002, Kidney international.

[11]  J. Ascaso,et al.  Cuantificación de insulinorresistencia con los valores de insulina basal e índice HOMA en una población no diabética , 2001 .

[12]  Mireia Junyent,et al.  Ecografía carotídea en la evaluación de aterosclerosis preclínica. Distribución de valores del grosor íntima-media y frecuencia de placas de ateroma en una cohorte comunitaria española , 2005 .

[13]  A. Smit,et al.  Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. , 2004, Circulation.

[14]  J. Paramo,et al.  Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors? , 2005, European heart journal.

[15]  E. Alegrı́a,et al.  Prevalencia del síndrome metabólico en población laboral española: registro MESYAS , 2005 .

[16]  Jing Chen,et al.  The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults , 2004, Annals of Internal Medicine.

[17]  J. Coresh,et al.  Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. , 2000, Kidney international.

[18]  M. Kubo,et al.  Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[20]  J. Díez,et al.  Estudio de riesgo vascular en Navarra: objetivos y diseño. Prevalencia del síndrome metabólico y de los factores mayores de riesgo vascular* , 2007 .

[21]  C. Stehouwer,et al.  Determinants of Progression of Microalbuminuria in Patients With NIDDM: A prospective study , 1997, Diabetes Care.

[22]  Z. Massy,et al.  Chronic kidney disease as cause of cardiovascular morbidity and mortality. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  L. Ruilope,et al.  Renal function: the Cinderella of cardiovascular risk profile. , 2001, Journal of the American College of Cardiology.

[24]  J. Shaw,et al.  The metabolic syndrome: prevalence in worldwide populations. , 2004, Endocrinology and metabolism clinics of North America.

[25]  N W Shock,et al.  Longitudinal Studies on the Rate of Decline in Renal Function with Age , 1985, Journal of the American Geriatrics Society.

[26]  D. Kang,et al.  Clinical implication of metabolic syndrome on chronic kidney disease depends on gender and menopausal status: results from the Korean National Health and Nutrition Examination Survey. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  C. Stehouwer,et al.  Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. , 2006, Journal of the American Society of Nephrology : JASN.

[28]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[29]  D. Sander,et al.  Kidney function and progression of carotid intima-media thickness in a community study. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  R. Krauss,et al.  Diagnosis and management of the metabolic syndrome , 2005 .

[31]  G. Chertow,et al.  Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. , 2005, Journal of the American Society of Nephrology : JASN.

[32]  J. Coresh,et al.  Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. , 2003, Kidney international.

[33]  Jiang He,et al.  Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. , 2006, The American journal of medicine.

[34]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[35]  G. Zalba,et al.  NADPH Oxidase—Dependent Superoxide Production Is Associated With Carotid Intima-Media Thickness in Subjects Free of Clinical Atherosclerotic Disease , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[36]  E. Ford,et al.  Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. , 2005, Diabetes care.

[37]  Matthias W. Lorenz,et al.  Prediction of Clinical Cardiovascular Events With Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis , 2007, Circulation.

[38]  M. Cirillo,et al.  Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. , 1998, Archives of internal medicine.

[39]  Daniel Levy,et al.  Predictors of new-onset kidney disease in a community-based population. , 2004, JAMA.

[40]  S. Grundy.  Metabolic Syndrome Pandemic , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[41]  Shankuan Zhu,et al.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of internal medicine.

[42]  B. Brenner,et al.  'Hypertension' and 'microalbuminuria': the bell tolls for thee. , 2006, Kidney international.

[43]  E. Ritz.  Minor renal dysfunction: an emerging independent cardiovascular risk factor , 2003, Heart.